Oncogenes play a key role in the development of various cancers, with PI3Ka being one of the most frequently mutated oncogenes across numerous cancer types. Mutations in PI3Ka occur in approximately 13% of all human cancers, with an even higher prevalence in breast cancer, affecting around 29% of cases. PI3KaH1047R is the most common mutation in PI3Ka.
The company we are profiling today is OnKure Therapeutics Inc. (OKUR), which is developing OKI-219, a novel therapeutic agent designed specifically to target the PI3Ka H1047R mutation.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.